☆ 4.6 Article

Adjuvant TACE may not improve recurrence-free or overall survival in HCC patients with low risk of recurrence after hepatectomy

FRONTIERS IN ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Surgery

Efficacy of Adjuvant Transarterial Chemoembolization after Radical Hepatectomy in Solitary Hepatocellular Carcinoma Patients: A Retrospective Study

Guifang Zeng et al.

Summary: This study found that for solitary hepatocellular carcinoma (SHCC) patients, postoperative adjuvant transarterial chemoembolization (PA-TACE) may not improve long-term survival and could potentially promote postoperative tumor recurrence, especially for those with negative microvascular invasion (MVI), tumor size <= 5 cm, and preoperative alpha-fetoprotein (AFP) < 400 ng/ml.

JOURNAL OF INVESTIGATIVE SURGERY (2022)

添加到收藏夹

Article Oncology

A 10-Gene Signature Identified by Machine Learning for Predicting the Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma

Yiyang Tang et al.

Summary: This study developed a machine learning model based on gene expression data to predict the response and prognosis of hepatocellular carcinoma (HCC) patients after transarterial chemoembolization (TACE) treatment. The model showed good discriminatory power in predicting TACE response and survival outcomes. The study also identified higher stemness index and more macrophage M0 cells in TACE nonresponders.

JOURNAL OF ONCOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Maria Reig et al.

Summary: There have been significant advances in the treatment strategies for hepatocellular carcinoma since the last update in 2018. However, some interventions still lack sufficient data for clinical incorporation, and personalized clinical management requires consideration of multiple parameters.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Recurrence hazard rate in patients with hepatocellular carcinoma and bile duct tumor thrombus: a multicenter observational study

Yan-Jun Xiang et al.

Summary: Patients with HCC BDTT have a high rate of postoperative recurrence. The hazard rate of intrahepatic recurrence was higher than that of extrahepatic recurrence, with both showing a decreasing trend. Anatomic hepatectomy and adjuvant TACE are recommended to improve BDTT patient outcomes.

HPB (2022)

添加到收藏夹

Review Medicine, General & Internal

Hepatocellular carcinoma

Arndt Vogel et al.

Summary: Hepatocellular carcinoma is a common cancer worldwide, with non-alcoholic fatty liver disease becoming a dominant cause. Treatment options are varied, including surgery, radiation, and medication. With the approval of new drugs and the development of immunotherapy, the outlook for hepatocellular carcinoma patients has improved, but the optimal sequencing of drugs and predictive biomarkers still need further research.

LANCET (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma

Soon Kyu Lee et al.

Summary: Hepatocellular carcinoma is a leading cause of cancer-related deaths globally, and early-stage patients can receive curative treatments such as surgical resection, liver transplantation, and percutaneous ablation. Despite the excellent long-term survival from these treatments, a high percentage of patients experience HCC recurrence, with tumor-related factors and the tumor microenvironment playing key roles. These recurrent mechanisms are being studied in ongoing adjuvant studies utilizing immune checkpoint blockers following curative treatments.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

添加到收藏夹

Letter Oncology

Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma

Lei Liang et al.

Summary: This study constructed an online calculator for assessing the survival benefit of adjuvant TACE for patients with resected HCC based on large-scale real-world data. By incorporating existing independent survival predictors, two prediction models were successfully developed and showed good calibration and discrimination.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Review Oncology

The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis

Jiarui Yang et al.

Summary: pa-TACE, postoperative radiotherapy, and sorafenib can improve the prognosis of patients with hepatocellular carcinoma with microvascular invasion after curative resection compared to postoperative conservative treatment. Postoperative radiotherapy can reduce the recurrence of patients with HCC with MVI after curative resection when compared to pa-TACE.

CANCER CELL INTERNATIONAL (2021)

添加到收藏夹

Article Oncology

A Novel Blood Index-Based Model to Predict Hepatitis B Virus-Associated Hepatocellular Carcinoma Recurrence After Curative Hepatectomy: Guidance on Adjuvant Transcatheter Arterial Chemoembolization Choice

Yiping Zou et al.

Summary: A reliable blood index-based model was constructed to predict hepatitis B virus-associated HCC recurrence after curative hepatectomy, guiding surgeons to select patients who may benefit from adjuvant treatment.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Adjuvant treatment strategy after curative resection for hepatocellular carcinoma

Wei Zhang et al.

Summary: Several adjuvant treatments have been evaluated for preventing HCC recurrence after curative liver resection, with antiviral therapy and postoperative adjuvant transarterial chemoembolization showing promising results. However, further large-scale randomized controlled trials are needed to confirm their efficacy in different patient populations.

FRONTIERS OF MEDICINE (2021)

添加到收藏夹

Review Medicine, General & Internal

Transcatheter arterial chemoembolization followed by surgical resection for hepatocellular carcinoma: a focus on its controversies and screening of patients most likely to benefit

Zhan-Qi Wei et al.

Summary: Surgical resection is recommended for hepatocellular carcinoma, but postoperative recurrence can impact long-term efficacy, making preoperative adjuvant therapy a research focus. While some studies support transcatheter arterial chemoembolization as a way to improve resection rates and reduce tumor recurrence, controversy remains.

CHINESE MEDICAL JOURNAL (2021)

添加到收藏夹

Article Oncology

A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma

Tian-En Li et al.

Summary: A novel immunotype-based risk stratification model was developed to predict postoperative prognosis and adjuvant TACE benefit in HCC patients by considering immune phenotype and PD-L1 expression.

JOURNAL OF CANCER (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis

Ai Shen et al.

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2020)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Resection Plus Post-operative Adjuvant Transcatheter Arterial Chemoembolization (TACE) Compared with Resection Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

Ya Ruth Huo et al.

CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma

Wen Chen et al.

HPB (2020)

添加到收藏夹

Review Oncology

Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update

Sirish A. Kishore et al.

CANCERS (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights

Di-Yang Xie et al.

HEPATOBILIARY SURGERY AND NUTRITION (2020)

添加到收藏夹

Article Oncology

Circulating tumor cells are an indicator for the administration of adjuvant transarterial chemoembolization in hepatocellular carcinoma: A single-center, retrospective, propensity-matched study

Peng-Xiang Wang et al.

CLINICAL AND TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Survival benefits from adjuvant transcatheter arterial chemoembolization in patients undergoing liver resection for hepatocellular carcinoma: a systematic review and meta-analysis

Lei Liang et al.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma

Young Chang et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Article Oncology

Postoperative Adjuvant Transarterial Chemoembolization Improves Outcomes of Hepatocellular Carcinoma Associated with Hepatic Vein Invasion: A Propensity Score Matching Analysis

Xiu-Ping Zhang et al.

ANNALS OF SURGICAL ONCOLOGY (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Does postoperative adjuvant transarterial chemoembolization benefit for all patients with hepatocellular carcinoma combined with microvascular invasion: a meta-analysis

Lei Wang et al.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2019)

添加到收藏夹

Article Oncology

Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis

Zhen-Hua Chen et al.

EJSO (2019)

添加到收藏夹

Article Oncology

Risk Factors for Deterioration of Remnant Liver Function After Hepatic Resection for Hepatocellular Carcinoma

Rui Marukuchi et al.

ANTICANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study

Zheng Wang et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Oncology

Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety

Wei Wei et al.

CANCER COMMUNICATIONS (2018)

添加到收藏夹

Article Oncology

Novel microvascular invasion-based prognostic nomograms to predict survival outcomes in patients after R0 resection for hepatocellular carcinoma

Long-Hai Feng et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)

添加到收藏夹

Review Gastroenterology & Hepatology

Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis

Mingheng Liao et al.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2017)

添加到收藏夹

Article Oncology

Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis

Xingshun Qi et al.

ONCOTARGET (2015)

添加到收藏夹

Review Oncology

Transarterial (chemo)embolization for curative resection of hepatocellular carcinoma: a systematic review and meta-analyses

Xiang Cheng et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)

添加到收藏夹

Review Gastroenterology & Hepatology

Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis

Jian-Hong Zhong et al.

HEPATOLOGY RESEARCH (2010)

添加到收藏夹

Article Surgery

Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus

Bao-Gang Peng et al.

AMERICAN JOURNAL OF SURGERY (2009)

添加到收藏夹

Article Oncology

A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma

Chong Zhong et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)

添加到收藏夹

Article Gastroenterology & Hepatology

Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma

Hui-Chuan Sun et al.

JOURNAL OF HEPATOLOGY (2007)

添加到收藏夹

Article Surgery

Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis - a randomized study

Q. Li et al.

WORLD JOURNAL OF SURGERY (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.